Gilead patent setback could limit protection for innovative combinations

19 September 2018
drugs_pills_tablets_big

UK-based drugmaker Accord Healthcare has won a key decision in the English High Court, paving the way for generic rivals to Gilead’s (Nasdaq: GILD) antiretroviral product Truvada (emtricitabine/tenofovir).

The latest chapter in a long-running dispute between the Californian drugmaker and generic firms, the court found that a Supplementary Protection Certificate (SPC) for Truvada was invalid, upholding similar decisions in the Court of Justice of the European Union.

The decision could impact other makers of combination anti-HIV treatments. Joseph Lenthall, a partner at Mewburn Ellis, told The Pharma Letter that the verdict “reinforces the jurisprudence that an SPC for a combination product cannot be based on a patent which does not relate 'necessarily and specifically' to that combination.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics